To Cite:
Komur
S, Kurtaran
B, Seza Inal
A, Pullukcu
H, Ulu
A, et al. Telaprevir Experience From Turkey,
Hepat Mon.
2015
;15(2):e25639.
doi: 10.5812/hepatmon.25639.
1.
Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81[DOI][PubMed]
2.
Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000; 20(1): 17-35[PubMed]
3.
European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
4.
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4): 1433-44[DOI][PubMed]
5.
Park C, Jiang S, Lawson KA. Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther. 2014; 39(1): 14-24[DOI][PubMed]
6.
McHutchison JG,
Manns MP,
Muir AJ,
Terrault NA,
Jacobson IM,
Afdhal NH,
et al.
Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14): 1292-303[DOI][PubMed]
7.
Zeuzem S,
Andreone P,
Pol S,
Lawitz E,
Diago M,
Roberts S,
et al.
Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364(25): 2417-28[DOI][PubMed]
8.
Akinci E, ÜNal Kayaaslan B, Tanrici BaŞBuĞ A, Sırrı Eren S, ÖNgÜRÜ P, Bodur H. Genotip 1b Kronik Hepatit C Hastalarında Kalıcı Virolojik Yanıtın Değerlendirilmesi. Viral Hepatit Dergisi. 2013; 19(2): 80-4[DOI]
9.
Shimada N,
Tsubota A,
Atsukawa M,
Abe H,
Ide T,
Takaguchi K,
et al.
A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study. Hepatol Res. 2014; 44(14)-96[DOI][PubMed]
10.
Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int. 2013; 33 Suppl 1: 30-4[DOI][PubMed]
11.
Cacoub P,
Bourliere M,
Lubbe J,
Dupin N,
Buggisch P,
Dusheiko G,
et al.
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2012; 56(2): 455-63[DOI][PubMed]
12.
McHutchison JG,
Everson GT,
Gordon SC,
Jacobson IM,
Sulkowski M,
Kauffman R,
et al.
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360(18): 1827-38[DOI][PubMed]
13.
Jacobson IM,
McHutchison JG,
Dusheiko G,
Di Bisceglie AM,
Reddy KR,
Bzowej NH,
et al.
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25): 2405-16[DOI][PubMed]
14.
Sherman KE,
Flamm SL,
Afdhal NH,
Nelson DR,
Sulkowski MS,
Everson GT,
et al.
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365(11): 1014-24[DOI][PubMed]
15.
Maasoumy B,
Port K,
Markova AA,
Serrano BC,
Rogalska-Taranta M,
Sollik L,
et al.
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One. 2013; 8(2)[DOI][PubMed]